Publications by authors named "A Afeltra"
Article Synopsis
- The study compared the safety and effectiveness of etanercept and adalimumab biosimilars (SB4 and ABP501) with their original versions among patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in Italy from 2017 to 2020.
- Out of 891 patients, safety profiles were similar; however, biosimilars had higher discontinuation rates due to ineffectiveness, with retention rates at 24 months being 76.5% for biosimilars compared to 81.1% for originators.
- The findings suggest biosimilars are a viable, safe, and more affordable treatment option, offering
Spondyloarthritis are chronic inflammatory diseases affecting spine, peripheral joints and enthesis, as well as extra-articular sites (bowel, eyes, skin). Diagnosis of spondyloarthritis often is slow and requires a multidisciplinary approach. The "Early SpA Clinic" project aimed at improving the patient care and journeys, by solving some organizational issues existing in Rheumatology Clinics.
View Article and Find Full Text PDFAn accurate prediction of cardiovascular (CV) risk in patients with Axial Spondyloarthritis (axSpA) is a strong unmet need, as CV risk algorithms poorly perform in these subjects. The aim of this study was to establish whether the persistence of high C-reactive protein (CRP) and high disease activity may be considered predictive factors of CVD in axSpA. 295 patients without personal history of CVD, were consecutively enrolled in this study.
View Article and Find Full Text PDFObjectives: Long-term quality of life (QoL) is significantly compromised in patients with psoriatic arthritis (PsA) and only partially improves achieving remission or low disease activity. The main aim of this study is to evaluate the QoL in PsA patients and to investigate their possible relationship with clinical remission and low disease activity, and with its duration over time.
Methods: A multicentre cross-sectional observational study has been performed.
Introduction: Aims of study were to evaluate the prevalence of metabolic syndrome (MetS) in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) patients and to evaluate serum level of adipokines in SLE and SSc patients with and without MetS.
Methods: Fifty SLE patients and 85 SSc patients were enrolled. The diagnosis of MetS was made according to the criteria of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III.